Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
STRO 
Sutro Biopharma (STRO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/21/2025: STRO (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
10 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $2.69
1 Year Target Price $2.69
| 4 | Strong Buy |
| 0 | Buy |
| 5 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -42.87% | Avg. Invested days 26 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/21/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 101.73M USD | Price to earnings Ratio - | 1Y Target Price 2.69 |
Price to earnings Ratio - | 1Y Target Price 2.69 | ||
Volume (30-day avg) 10 | Beta 1.62 | 52 Weeks Range 0.52 - 4.60 | Updated Date 10/21/2025 |
52 Weeks Range 0.52 - 4.60 | Updated Date 10/21/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.51 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -199.76% | Operating Margin (TTM) 23.65% |
Management Effectiveness
Return on Assets (TTM) -27.54% | Return on Equity (TTM) -347.64% |
Valuation
Trailing PE - | Forward PE 10.03 | Enterprise Value -109046261 | Price to Sales(TTM) 0.97 |
Enterprise Value -109046261 | Price to Sales(TTM) 0.97 | ||
Enterprise Value to Revenue 0.36 | Enterprise Value to EBITDA 0.41 | Shares Outstanding 84774177 | Shares Floating 67025008 |
Shares Outstanding 84774177 | Shares Floating 67025008 | ||
Percent Insiders 4.71 | Percent Institutions 62.84 |
Upturn AI SWOT
Sutro Biopharma
Company Overview
History and Background
Sutro Biopharma, Inc. was founded in 2003. It is a clinical-stage drug discovery, development and manufacturing company focused on oncology and autoimmune diseases.
Core Business Areas
- Drug Discovery and Development: Sutro is focused on the discovery and development of cancer and autoimmune therapeutics. Its technology enables rapid drug design and development, which accelerates clinical development timelines.
- Manufacturing: Sutro also provides manufacturing services for its own drug candidates and for partners.
Leadership and Structure
The leadership team includes Bill Newell (CEO). The company has a typical biotech organizational structure with departments focused on R&D, clinical development, manufacturing, and business operations.
Top Products and Market Share
Key Offerings
- STRO-002 (FolRu03b1 ADC): A folate receptor alpha (FolRu03b1)-targeting antibody-drug conjugate (ADC) in Phase 2 clinical trials for ovarian cancer and endometrial cancer. Competitors include ImmunoGen(IMGN) with Elahere, a FolRu03b1 ADC approved for ovarian cancer.
- STRO-003 (CD74 ADC): A CD74-targeting antibody-drug conjugate (ADC) in Phase 1 clinical trials for B-cell malignancies. Competitors include companies developing other CD74-targeting therapies.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. There is significant activity and investment related to ADC development.
Positioning
Sutro is a clinical-stage biotech company focused on ADC therapeutics. Their technology allows for rapid design and development, giving them a competitive advantage.
Total Addressable Market (TAM)
The TAM for ADCs is substantial, estimated to be in the tens of billions of dollars. Sutro Biopharma is positioned to capture a portion of this market with its pipeline of ADC candidates.
Upturn SWOT Analysis
Strengths
- Proprietary cell-free protein synthesis technology
- Strong preclinical and clinical pipeline
- Strategic partnerships with major pharmaceutical companies
Weaknesses
- Reliance on clinical trial success
- High cash burn rate
- Relatively small market capitalization compared to competitors
Opportunities
- Advancement of pipeline candidates through clinical trials
- Expansion of partnerships
- Potential for acquisition by a larger pharmaceutical company
Threats
- Clinical trial failures
- Competition from other biotechnology and pharmaceutical companies
- Regulatory hurdles
- Economic downturn affecting investment in biotech
Competitors and Market Share
Key Competitors
- IMGN
- MRNA
- BMRN
Competitive Landscape
Sutro's competitive advantage lies in its proprietary technology platform that enables rapid drug design and development. However, it faces competition from larger, more established pharmaceutical companies with greater resources.
Growth Trajectory and Initiatives
Historical Growth: Sutro has grown through its partnerships and clinical development programs.
Future Projections: Future growth is dependent on the successful development and commercialization of its pipeline candidates. Analyst projections vary but generally anticipate significant revenue growth if STRO-002 and STRO-003 achieve regulatory approval.
Recent Initiatives: Recent initiatives include advancing STRO-002 into Phase 2, initiating Phase 1 for STRO-003, and securing additional partnerships.
Summary
Sutro Biopharma is a clinical-stage company with a promising technology platform and pipeline of ADC candidates. Its success hinges on the advancement of its lead programs through clinical trials and eventual regulatory approval. The high cash burn rate and reliance on clinical success are risks that investors should consider. Strong partnerships and potential acquisitions could accelerate growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Sutro Biopharma's website
- SEC filings
- Analyst reports
- Industry publications
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share data is based on estimates and may not be precise. Investment decisions should be made after consulting with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Sutro Biopharma
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2018-09-27 | CEO & Director Ms. Jane Chung R.Ph. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 244 | Website https://www.sutrobio.com |
Full time employees 244 | Website https://www.sutrobio.com | ||
Sutro Biopharma, Inc. operates as a oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+. Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. The company also develops VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors, such as triple negative breast cancer, non-small cell lung cancer, and ovarian cancer, as well as hematological cancers. Sutro Biopharma, Inc. has collaboration and license agreements with Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; Ipsen to develop and commercialize STRO-003, an ADC targeting ROR1; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.